Skip to Content

Olysio Side Effects

Generic Name: simeprevir

Note: This page contains side effects data for the generic drug simeprevir. It is possible that some of the dosage forms included below may not apply to the brand name Olysio.

For the Consumer

Applies to simeprevir: oral capsule

As well as its needed effects, simeprevir (the active ingredient contained in Olysio) may cause unwanted side effects that require medical attention.

Severity: Major

If any of the following side effects occur while taking simeprevir, check with your doctor immediately:

More common
  • Blistering, crusting, irritation, itching, or reddening of the skin
  • cracked, dry, or scaly skin
  • difficult or labored breathing
  • increased sensitivity of the skin to sunlight
  • rash with flat lesions or small raised lesions on the skin
  • rash, itching skin
  • redness or other discoloration of the skin
  • severe sunburn
  • tightness in the chest

Severity: Minor

Some simeprevir side effects may not need any medical attention. As your body gets used to the medicine these side effects may disappear. Your health care professional may be able to help you prevent or reduce these side effects, but do check with them if any of the following side effects continue, or if you are concerned about them:

More common
  • Difficulty with moving
  • joint pain
  • muscle aching or cramping
  • muscle pains or stiffness
  • nausea
  • swollen joints

For Healthcare Professionals

Applies to simeprevir: oral capsule

Hepatic

Grade 1, 2, 3, and 4 hyperbilirubinemia were reported in 26.7%, 18.3%, 4.1%, and 0.4% of patients, respectively. Bilirubin elevations were mostly mild to moderate in severity, and included elevation of both direct and indirect bilirubin. Bilirubin elevations occurred soon after therapy started, peaked by the second week, and reversed quickly after this drug was stopped. In general, bilirubin elevations (direct and indirect) were not associated with liver transaminase elevations. The incidence of increased bilirubin was higher in patients with increased simeprevir (the active ingredient contained in Olysio) exposures.

Compared to a pooled phase 3 population from global trials, East Asian patients using this drug with peginterferon alfa and ribavirin had a higher incidence of hyperbilirubinemia; elevated total bilirubin (all grades) was reported in up to 66% of patients. Bilirubin elevations were primarily grade 1 or 2; grade 3 bilirubin elevations were reported in up to 9% of patients. Bilirubin elevations were not associated with liver transaminase elevations and were reversible after therapy ended.

Increased bilirubin was reported in 0% of patients using this drug with sofosbuvir and 9% using this drug with sofosbuvir and ribavirin.

Hepatic decompensation and hepatic failure (including fatalities) have been reported with this drug coadministered with peginterferon alfa and ribavirin or with sofosbuvir. Most reports occurred in patients with advanced and/or decompensated cirrhosis.[Ref]

Dermatologic

Very common (10% or more): Rash (including photosensitivity; term included rash, erythema, eczema, maculopapular rash, macular rash, dermatitis, papular rash, skin exfoliation, pruritic rash, erythematous rash, urticaria, generalized rash, drug eruption, allergic dermatitis, dermatosis, vasculitic rash, toxic skin eruption, exfoliative rash, generalized erythema, exfoliative dermatitis, cutaneous vasculitis, photosensitivity reaction, polymorphic light eruption, solar dermatitis, photodermatosis, sunburn, blister, macule, erythema of eyelid, palmar erythema, papule, pityriasis rosea, follicular rash, morbilliform rash, pustular rash, scrotal erythema, skin irritation, skin reaction, umbilical erythema; up to 28%), pruritus (term included pruritus, generalized pruritus, eyelids pruritus, prurigo; up to 22%)
Common (1% to 10%): Photosensitivity reaction[Ref]

Fifty-six percent (56%) of rash events occurred in the first 4 weeks; 42% in the first 2 weeks. Most rash and pruritus events were of mild or moderate severity. Severe rash was reported in up to 1% of subjects. This drug was discontinued due to rash in up to 1% of subjects. The frequencies of rash and photosensitivity reactions were higher in subjects with higher simeprevir exposures.

Rash was reported in 20% of patients using this drug with sofosbuvir and ribavirin and up to 11% using this drug with sofosbuvir. Pruritus was reported in 11% of patients using this drug with sofosbuvir.

All trial subjects were directed to use sun protection measures. Most photosensitivity reactions were of mild or moderate severity. Two subjects had photosensitivity reactions that required hospitalization.

Photosensitivity reactions were reported in 7% of patients using this drug with sofosbuvir and 6% using this drug with sofosbuvir and ribavirin.[Ref]

Other

Fatigue was reported in 25% of patients using this drug with sofosbuvir.

Very common (10% or more): Fatigue (25%)

Gastrointestinal

Very common (10% or more): Nausea (up to 22%), diarrhea (16%)
Common (1% to 10%): Constipation[Ref]

Nervous system

Very common (10% or more): Headache (21%), dizziness (16%)

Headache was reported in 21% of patients using this drug with sofosbuvir.

Dizziness was commonly reported during 24 weeks therapy with this drug and sofosbuvir.

Musculoskeletal

Very common (10% or more): Myalgia (16%)[Ref]

Psychiatric

Very common (10% or more): Insomnia (14%)

Insomnia was reported in 14% of patients using this drug with sofosbuvir.

Hematologic

Anemia was reported in 13% of patients using this drug with sofosbuvir and ribavirin and 0% using this drug with sofosbuvir.

A higher incidence of anemia was reported in patients with advanced fibrosis.

Very common (10% or more): Anemia (up to 13%)

Respiratory

Very common (10% or more): Dyspnea (term included dyspnea, exertional dyspnea; 12%)[Ref]

Metabolic

Common (1% to 10%): Increased alkaline phosphatase[Ref]

Grade 1 and 2 alkaline phosphatase elevations were reported in 3.3% and 0.1% of patients, respectively.[Ref]

Cardiovascular

Postmarketing reports: Symptomatic bradycardia (including cases requiring pacemaker intervention)

References

1. Cerner Multum, Inc. "UK Summary of Product Characteristics." O 0

2. "Product Information. Olysio (simeprevir)." Janssen Pharmaceuticals, Titusville, NJ.

It is possible that some side effects of Olysio may not have been reported. These can be reported to the FDA here. Always consult a healthcare professional for medical advice.

Disclaimer: Every effort has been made to ensure that the information provided is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate safety, effectiveness, or appropriateness for any given patient. Drugs.com does not assume any responsibility for any aspect of healthcare administered with the aid of materials provided. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the substances you are taking, check with your doctor, nurse, or pharmacist.

Hide